Back to Results
First PageMeta Content
Emergency contraception / Levonorgestrel / Mifepristone / Yuzpe regimen / Progesterone / Selective progesterone receptor modulator / Birth control / Contraception / Hormonal contraception / Endocrine system / Ulipristal acetate


U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived
Add to Reading List

Open Document

File Size: 708,82 KB

Share Result on Facebook

Company

PK SAE SD SPA / UPI US / Definitions AE / ITT / HRA Pharma / /

Country

United States / United Kingdom / Ireland / /

Currency

pence / /

Event

FDA Phase / /

Facility

SPA SPRM TVUS UPA / Laboratory Findings / /

IndustryTerm

healthcare provider education / drug product / dedicated products / /

MedicalTreatment

oral contraceptives / birth control / EMERGENCY CONTRACEPTION / contraception / /

MusicGroup

Step / Plan B / /

Organization

Advisory Committee for Reproductive Health Drugs / Reproductive and Urologic Products Office / World Health Organization / OR PD / European Medicines Agency / U.S. Food and Drug Administration / US Federal Reserve / Review Division / Division of Reproductive / Urologic Products Office / New Drugs Center for Drug Evaluation / Advisory Committee / /

Product

Dosing Regimen One 30 / LEVONORGESTREL / estradiol / chorionic gonadotropin / Preven / misoprostol / Ulipristal / EC / US / ULIPRISTAL FOR EMERGENCY / Dosing / HRA2914-509 / P450 / FDA-Approved Drug / /

ProgrammingLanguage

EC / /

Technology

Pharmacokinetics / ultrasound / Pharmacodynamics / /

SocialTag